Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen

Abstract

Objective: To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden.Design: A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects.Setting: Primary care.Patients: Patients with moderate hypertension and three or more additional risk factors.Interventions: Amlodipine 5-10 mg with perindopril 4 8 mg added as needed or atenolol 50-100 mg with bendroflumethiazide 1.25-2.5 mg and potassium added as neededMain outcome measures: Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained.Results: In the UK, the cost to avoid one cardiovascular event or procedure would be (sic)18 965, and the cost to gain one quality-adjusted life-year would be (sic)21 875. The corresponding figures for Sweden were (sic)13 210 and (sic) 856.Conclusions: Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare's Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol- based regimen in the population studied.